Ventus Therapeutics Begins Phase 1 Trial of Neuroinflammation Treatment
By Exec Edge Editorial Staff Ventus Therapeutics said it initiated Phase 1 testing for VENT-02, an orally administered NLRP3 inhibitor with remarkable brain penetration. The trial with healthy volunteers aims to explore VENT-02’s impact on neuroinflammatory diseases, such as Parkinson’s...